Research programme: metal-protein-attenuating compounds - Prana Biotechnology

Drug Profile

Research programme: metal-protein-attenuating compounds - Prana Biotechnology

Alternative Names: MPAC - Prana Biotechnology; PBT 519; PBT-434; PBT3 series - Prana Biotechnology; PBT4 series - Prana Biotechnology

Latest Information Update: 13 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Prana Biotechnology
  • Class Quinazolinones
  • Mechanism of Action Alpha-synuclein inhibitors; Dopamine modulators; Iron chelating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Brain cancer; Parkinson's disease
  • Research Neurodegenerative disorders
  • Discontinued Age-related macular degeneration; Alzheimer's disease

Most Recent Events

  • 13 Apr 2018 Preclinical development for Parkinson's disease is ongoing in Australia (PO)
  • 21 Mar 2018 Prana Biotechnology plans a phase I trial for Parkinson's disease (In volunteers) in Australia in May 2018 (ACTRN12618000541202p)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Parkinson's-disease in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top